Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03719053 · ClinicalTrials.gov registry record · Phase 1
Single Dose Truvada Study
A Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT03719053: Completed Phase 1 study, sponsored by Johns Hopkins University.
NCT03719053 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03719053, a Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This study examines tenofovir (TFV) drug concentrations in adults one day after taking a single dose of Truvada® - a pill used to prevent and treat HIV infection. The results of this study will be used to improve the (efficacy/accuracy) of a white coat adherence (WCA) detection test - a blood test that can be used to indicate medication adherence. Participants will receive one dose of Truvada®, and provide 2 total samples of blood.
Interventions
- DRUG Tenofovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2018-10-25 |
| Est. Completion | 2020-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03719053
The ClinicalTrials.gov registry entry for NCT03719053 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tenofovir is the first listed.
NCT03719053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03719053 about?
NCT03719053 is a clinical study titled "Single Dose Truvada Study". This study examines tenofovir (TFV) drug concentrations in adults one day after taking a single dose of Truvada® - a pill used to prevent and treat HIV infection. The results of this study will be used to improve the (efficacy/accuracy) of a white coat adherence (WCA) detection test - a blood test t...
What is the current status of trial NCT03719053?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2018-10-25. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT03719053?
The interventions under investigation include: Tenofovir (DRUG).
Who is sponsoring clinical trial NCT03719053?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.